<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05071495</url>
  </required_header>
  <id_info>
    <org_study_id>2020/171</org_study_id>
    <nct_id>NCT05071495</nct_id>
  </id_info>
  <brief_title>TeleDiet Study: The Impact of Dietary Education and Counseling With a Smartphone Application on Secondary Prevention of Coronary Artery Disease</brief_title>
  <official_title>TeleDiet Study: A Randomized Controlled Study Investigating the Impact of Dietary Education and Counseling With a Smartphone Application on Secondary Prevention of Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jessa Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jessa Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Digital cardiology is gaining power in the field of preventive cardiology recently, and&#xD;
      several trials have already shown good results of dietary therapy with digital cardiology.&#xD;
      However, there has been no reports that showed effect of dietary counseling through digital&#xD;
      cardiology for secondary prevention of coronary artery disease.&#xD;
&#xD;
      TeleDiet study investigates the impact of dietary therapy with a smartphone application on&#xD;
      the content of meals and metabolic parameters for patients with coronary artery disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 17, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MedDiet score (the Mediterranean diet score)</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>This score has the extreme values of 0 (minimum) and 55 (maximum). Higher scores mean a better outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood lipid tests (LDL-cholesterol [LDL-C], HDL-cholesterol [HDL-C], and triglyceride [TG])</measure>
    <time_frame>Up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood glycated hemoglobin (HbA1c) test</measure>
    <time_frame>Up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood creatinine (Cr) test</measure>
    <time_frame>Up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parameters in the ergospirometer test (maximal oxygen consumption [VO2 max])</measure>
    <time_frame>Up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parameters in the ergospirometer test (anaerobic threshold [AT])</measure>
    <time_frame>Up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Values of self-efficacy (questionnaire of General Self-Efficacy Scale [GSE])</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>This scale has the extreme values of 10 (minimum) and 40 (maximum). Higher scores mean a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Values of medication adherence (questionnaire of Identification of Medication Adherence Barriers [IMAB])</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>This scale has the extreme values of 30 (minimum) and 150 (maximum). Higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Values of quality of life (Health-related Quality of Life questionnaire [HeartQoL])</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>This scale has the extreme values of 0 (minimum) and 42 (maximum). Higher scores mean a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight (BW)</measure>
    <time_frame>Up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body mass index (BMI)</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Weight and height will be combined to report BMI in kg/m^2.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Smartphone application</intervention_name>
    <description>Smartphone application named &quot;Signal&quot;, which connects patients and health providers</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Owning a smartphone and able to use it&#xD;
&#xD;
          2. Written informed consent obtained&#xD;
&#xD;
          3. Starting cardiac rehabilitation&#xD;
&#xD;
          4. Coronary artery disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Special diet due to other reasons (eg. renal diet, pancreatic insufficiency diet)&#xD;
&#xD;
          2. Age &lt;18 years old&#xD;
&#xD;
          3. Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Dendale</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jessa Ziekenhuis vzw</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toshiki Kaihara</last_name>
    <phone>+32485955378</phone>
    <email>m03014tk@jichi.ac.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maarten Folter</last_name>
    <email>Maarten.Falter@jessazh.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jessa Hospital</name>
      <address>
        <city>Hasselt</city>
        <state>Limburg</state>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toshiki Kaihara</last_name>
      <phone>+32485955378</phone>
      <email>m03014tk@jichi.ac.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 13, 2021</study_first_submitted>
  <study_first_submitted_qc>September 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Secondary Prevention</keyword>
  <keyword>Diet Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

